Trial Profile
An Open-Label Rollover Study of PBI 4050 in Subjects With Alstrom Syndrome
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Fezagepras (Primary)
- Indications Alstrom's Syndrome
- Focus Adverse reactions; Registrational
- Sponsors Liminal BioSciences; ProMetic Biosciences
- 07 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 20 May 2019 New source identified and integrated(European Clinical Trials Database)
- 16 May 2019 Status changed from recruiting to active, no longer recruiting.